Table 2.
Transcription Codes Categorized Through Themes
| Code | Description | Focus group | Interview 1 | Interview 2 | Interview 3 | Interview 4 | PPI café |
|---|---|---|---|---|---|---|---|
| CDMP-product perceptions | |||||||
| Licensed use | What conditions can CDMP be used in? | ✓ | ✓ | ✓ | ✓ | ✓ | |
| Medicinal benefits | Symptom control and actions of CDMP which provide medical benefit | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Side effects of CDMPs | Perceptions of CDMP side effects | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Safety | Perceptions about the safety of CDMPs | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Production | Beliefs about the production of legal and illegal cannabis | ✓ | |||||
| Availability | Access and costs of CDMPs | ✓ | |||||
| Addiction of CDMPs | Beliefs about the risk of addiction to CDMPs and illicit cannabinoids | ✓ | ✓ | ✓ | ✓ | ✓ | |
| CDMPs and mental health | Beliefs about the effects of CDMPs and cannabis on population mental health | ✓ | ✓ | ||||
| Cannabis laws | Perceptions about the legal availability of CDMPs and cannabis | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Cannabis and religion | Religious implications of cannabis use | ✓ | |||||
| CDMPs and the media | Media portrayal of CDMP use | ✓ | ✓ | ✓ | ✓ | ||
| Personal CDMP use | Personal experience with CDMP—benefits and harms | ✓ | |||||
| Personal cannabis use | Personal experiences with cannabis | ✓ | ✓ | ||||
| Medical administration of CDMPs | Best methods to improve acceptability of CDMPs when taking in a medical context. | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Opioid perceptions | |||||||
| Medicinal benefits of opioids | Symptom control and actions of opioids which provide medical benefit | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Side effects of opioids | Perceptions about opioid side effects | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Opioid addiction | Beliefs about the risk of addiction to opioids | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Trial perceptions | |||||||
| Consent | How best to conduct consent and relay information about the trial to lay persons | ✓ | ✓ | ||||
| Pain | Thoughts about how to best assess pain | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Nausea and vomiting | Ideas about how to best measure nausea and vomiting | ✓ | |||||
| Postoperative side effects | Beliefs about how we could best capture side effects and what side effects are unacceptable in the postoperative period | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Quality of life | Encompassing of general quality of life as an endpoint | ✓ | |||||
| Frequency of data collection | How often patients should be asked about primary endpoints | ✓ | ✓ | ✓ | |||
| Night-time data capture | Thoughts about whether data capture should continue overnight | ✓ | ✓ | ||||
| Length of follow-up | How best to follow up patients | ✓ | |||||
| Participation | Factors that contribute to patient's attitudes toward taking part in the research. | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
PPI, patient and public involvement.